window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Development

  • Partnerships & Funding

    Immunai and Parker Institute partner on landmark single-cell cancer dataset

    April 25, 2025
  • Drug Development

    Landmark BioVentures and G.CLIPS Biotech join forces to tackle drug target engagement bottlenecks

    April 24, 2025
  • Cell & Gene Therapy

    Hydrogel breakthrough could boost liver cell therapy durability, Likarda paper shows

    April 24, 2025
  • Clinical Trials

    Shilpa Medicare’s Nor-UDCA tablets advance in India: SEC recommends marketing authorization following positive phase 3 results

    April 22, 2025
  • Clinical Trials

    AI appetite slows as clinical trial leaders refocus on risk-based strategies

    April 22, 2025
  • Movers & Shakers

    New independent pharma news platform, Discover Pharma, launches

    April 24, 2025
Previous910

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Cereno Scientific reports long-term safety data from CS1 pulmonary arterial hypertension program
    Categories: Cardiovascular diseases, Clinical Trials, Rare Diseases, Regulatory Affairs, Research & Development
  • City St George’s and Paradigm Biopharmaceuticals study osteoarthritis pain drug mechanism
    Categories: Clinical Trials, Neurosciences, Partnerships & Funding, Research & Development
  • BIOGRUND and Seprify launch plant-based tablet coating to replace titanium dioxide
    Categories: Ingredients, Manufacturing, Packaging, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top